

39
40
41
42
43
44
45

INTRODUCTION

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome [1]. AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype [2]. Infection with HIV occurs by the transfer of blood, pre-ejaculate, semen, vaginal fluids, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.

Comment [ZK8]: sentence complex.

Comment [ZK9]: Word choice problem

One-third of the world's population is thought to be infected with TB. New infections occur in about 1% of the population each year [3]. In 2014, there were 9.6 million cases of active TB which resulted in 1.5 million deaths. More than 95% of deaths occurred in developing countries. The number of new cases each year has decreased since 2000. About 80% of people in many Asian and African countries test positive while 5-10% of people in the United States population tests positive by the tuberculin test [4]. Tuberculosis has been present in humans since ancient times [5].

Comment [ZK10]: No idea fluency is found here

Comment [ZK11]: Why did the number of positive cases decline?

Pulmonary TB causes bleeding disorders. Hematologic abnormalities have been described in association with mycobacteria infections for almost 100 years. Also activation of coagulation and fibrinolytic pathways in response to various bacterial infections are critical component elicited by both pathways [6]. Experimental studies also confirmed impairment in coagulation parameters in patients with alcoholic pulmonary TB.

Comment [ZK12]: Grammar check

Comment [ZK13]: The introduction part is missing fluency of information, also the purpose of the study is not mentioned

MATERIALS AND METHODS

Study Area

This research was conducted at HIV and TB clinics of Federal Medical Centre, Owerri with co-ordinate location of latitude 5°28 '59 "N and 7° OF 49' E longitude and 159metres above sea level.

Study Population

This study was carried out on both male and female already established to be HIV and TB patients attending Federal Medical Centre, Owerri, Imo State Nigeria for treatment and check-up. People of the same age group and sex was used as control who prior to this research have not been diagnosed of HIV and TB.

Comment [ZK14]: Word choice problem

Comment [ZK15]: Grammar error

Ethnical Consideration

Ethnical consideration for this research was obtained from the federal medical centre Owerri, Imo State.

Sample Size and Sampling Techniques

A total sample size of 60 was collected 45 test subjects (15 patients with HIV only, 15 patients with TB only and 15 TB patients with. HIV {Co-infection}) and 15 control subjects

Comment [ZK16]: What does this mean?

83 (Non HIV and TB). The test population comprised of individuals who are within the age
84 bracket of 20 and 50. While the control group was made up of individuals who have been
85 tested and confirmed to be non-HIV and non-TB as at the time this research was carried out
86 who are within the afore mentioned age bracket.
87 Subjects were recruited by random sampling techniques.

88 89 **Subject Recruitment**

90 All consenting HIV and TB patients were recruited for the study in their clinic during their
91 clinic days through the help of the nurses and physicians after a well and elaborate
92 explanation of the importance of the study, as well as the harmless nature of the procedure for
93 the sample collection. An informed consent of individual patient was obtained before
94 recruitment. The same was applied to the control group.

95 **Inclusion Criteria**

96 The criteria for selecting test subjects for this research included: willingness to participate,
97 subject could be male or female, must be up to 20years and not more than 80years of age,
98 must have been diagnosed of HIV and TB according to WHO standard.

99 100 **Exclusion Criteria**

101 Criteria for excluding test subjects includes: people with established coagulation problems,
102 those not diagnosed of HIV and TB according to WHO standard, those below 20years of age
103 and above 50years of age, those with other complications of HIV and TB.

104 105 **Sample Collection, Preparation and Storage**

106 Nine (9) ml of various blood was collected from every participant into 1 ml of 3.8% sodium
107 citrate anticoagulant both, well mixed and centrifuged at 1200g for 15mins to obtain platelet
108 poor plasma. The plasma was then separated to a plain container, labeled properly and the
109 test performed immediately. Some of the test sample that could not be analysed immediately
110 was stored at 4-8°C and the test performed within 1 hour of storage.
111 Questionnaire was issued to the participants to obtain other vital information about them.

Comment [ZK17]: tube

112 113 **METHODOLOGY**

114 **Activated Partial Thromboplastin Time Estimation**

115 Method: Kaolin platelet substitute mixture

116 **Procedure**

117 In a small glass tube, 0.2ml of well mixed Kaolin/platelet substitute was pipetted 0.1ml of the
118 separated plasma was added, mixed and incubated at 37°C for exactly 2minutes. The tube was
119 tilted at intervals.
120 0.1ml of 0.025 mol/L calcium chloride was added, mixed and the stop watch started.
121 The tube was held in water bath and the mixture tilted back and forth looking out for clot
122 formation. The stop-watch was stopped immediately clot formation was observed and the
123 time recorded.

Comment [ZK18]: No need to repeat the word methodology

Comment [ZK19]: Cite the mentioned method

Comment [ZK20]:

Comment [ZK21]: How long did the interval set?

Comment [ZK22]: Conjunction is required such as when

124 125 **Prothrombin Time Estimation**

126 Method: Diagen Rabbit Brain capillary reagent

127 **Procedure**

- 128 1. 0.25ml of the thromboplastin/calcium reagent was pipetted into a small glass tube and
129 placed in a 37°C water bath for 2mintues.
- 130 2. 50ul (0.05ml) of plasma was added using delivery pipette, mixed and the stop watch
131 started.
- 132 3. The tube was held in the water bath and the mixture tilted back and forth looking out for

Comment [ZK23]: Cite the method

133 clot formation. The stop-watch is stopped when clot begins to form.
134 4. The control sample was also run with the test sample using the same procedure
135 Calculation
136 The result gotten in seconds was converted into INR (International Normalised Ratio) as
137 follows:

$$INR = \left(\frac{PT \text{ patient}}{PT \text{ control}} \right) ISI$$

138 ISI = International Sensitivity Index which is provided by the manufacturer of the
139 thromboplastin reagent.

140 **STATISTICAL ANALYSIS**

142 The results were expressed as mean± standard deviation. The student t-test was used to
143 compare the parameters (at level of significance 0.05) $p < 0.05$ was considered as statistical
144 significant and $p > 0.05$ was considered not statistically significant.

Comment [ZK24]: Please explain your comparison groups

147 **RESULT AND ANALYSIS**

148 **Table 1: Mean and Standard deviation of PT and APTT of control and HIV patients.**

Parameters	Control (n=15)	HIV patients (n=15)	p-value
PT (sec)	12.45 ± 1.23	15.45 ± 1.44* [^]	P< 0.05
APTT (sec)	29.05 ± 2.19	33.33 ± 6.27	P< 0.05

149

150 Key: *: Statistically significant when compared with control

151 PT: Prothrombin time.

152 APTT: Activated partial thromboplastin time.

153 N: Sample size

154 From the table 1 above, PT of HIV patients (15.45±1.44sec) was statistically significantly
155 (p<0.05) higher when compared with the control (12.45 + 1,23sec).

156 APTT of HIV patients (33.33±6.27sec) was not statistically higher (p>0.05) than the control
157 (29.05±2.19sec).

158

Comment [ZK25]: The text of info should proceed the table

159 **Table 2: Mean ad Standard deviation of PT APTT of TB patients and control**

160

Parameters	Control (n=15)	TB patients (n=15)	p-value
PT (sec)	12.45 ± 1.23	15.45 ± 1.44* [^]	P< 0.05
APTT (sec)	29.05 ± 2.19	33.33 ± 6.27	P< 0.05

161

162 Key *: Statistically significant (P< 0.05) when compared with the control.

163 Comparism between the PT mean of TB patient (15.84±0.98scc) and control (12.45
164 +1.28sec) shows a statistical significantly (p<0.05) higher value in TB patient. The APTT
165 value of TB patient was not significantly (p>0.05) higher in TB (33.55±5.26sec) patients
166 when compared with the control subjects. (29.05±2,19sec).

167

Comment [ZK27]: Grammar check

Comment [ZK28]: Suggestion: Why did you not combine the results of HIV and TB in one table?

168

Comment [ZK29]: The results explanation should proceed the table

169 **Table 3:** Comparism of mean and standard deviation of PT and APTT of HIV & TB co-
170 infected subjects and control.

Comment [ZK30]: Grammar check

Parameters	Control (n=15)	HIV/ TB patients (n=15)	p-value
PT (sec)	12.45 ± 1.23	15.45 ± 1.44* [^]	P< 0.05
APTT (sec)	29.05 ± 2.19	35.59 ± 4.69*	P< 0.05

171

172 Key *: statistically significantly higher when compared with the control.

173 From table 3 above, the PT of HIV & Tb co- infected subjects (17.03 ± 1.46sec) was
174 significantly higher (P< 0.05) than the control (12.45 ± 1.23sec). APTT of HIV & TB co-
175 infected patients (37.59 ± 4.69sec) was significantly higher than the control (29.05 ±
176 2.19sec).
177

Comment [ZK31]: Grammar error

Comment [ZK32]: grammar

Comment [ZK33]: Same as above, all results explanation phrases should proceed the table of info, all above results can be incorporated into one table

178

179 **Table 4: Mean and standard deviation of prothrombin time (PT) and a activated partial**
 180 **thromoplastin time (APTT) of HIV, TB and co-infected**

Comment [ZK34]: Place the table after the text of information

	HIV Group 2	TB Group 3	HIV/TB Group 4
PT (sec)	15.45 ± 1.44	15.48 ± 0.98*	17.03 ± 1.46
APTT (sec)	33.33 ± 6.27	33.55 ± 5.26*	37.59 ± 4.69

Comment [ZK35]: Significant or not?

181

182 Key *: Statistically significant when compared with HIV patient (P< 0.05).

183 PT: Prothromobin time

184 APTT: Activated partial thromboplastic time

185 The table below indicates mean and standard deviation of PT and APTT of HIV, TB and
 186 HIV/TB co-infected groups when compared among each other. From the table, one way
 187 analysis of variance shows that a PT of TB patient (15.84+0.98) was not significantly higher
 188 than HIV patients (15.45+1.44sec). PT of HIV and TB co- infection was significantly
 189 (p<0.05) higher when compared with HIV patients but not significantly (p>0.05) higher when
 190 compared with TB patients.

Comment [ZK36]: Why did you put the star mark if it's not significant?

191 Comparism of APTT among HIV patient (33.33+6.27) TB patient (33.55±5.25) and HIV/TB
 192 co-infected patient (37.59+4.69) shows an increase in TB patients when compared with HIV
 193 patient. APTT level of HIV & TB co-infected patient when compared with HIV and TB
 194 patient shows a non-significant higher value in HIV and TB patients.

Comment [ZK37]: Use past tense

Comment [ZK38]: Did you mean HIV?

Comment [ZK39]: The paragraph should be placed before the table

195

196 **DISCUSSION**

197 Both hematological and haemostatic disorders are known complications of HIV infection.
 198 HIV infection is associated with endothelial dysfunction and liver damage which can result in
 199 coagulation defects. It is therefore expected that as the HIV infection progresses the
 200 coagulation abnormalities will increase too [7]. In this study The PT and APTT were
 201 significantly higher in HIV-positive subjects (ART and non-ART) compared to the values
 202 obtained in the HIV-negative subjects (control). (p<0.05) and is in consonance with previous
 203 independent studies of Van Gorpet., *et al*[8] Omoregie *et al* [9] Obeagu and Obeagu [10].
 204 These studies reported that PT and APTT were significantly higher in HIV-positive patients.
 205 Moreover, HIV infection results in liver derangement, immune dysregulation and presence of
 206 anticardiolopin antibodies (aCL) and Lupus anticoagulant (LA). These anomalies of clotting
 207 factors, liver derangement may account for higher PT and APTT values observed in HIV-
 208 positive subjects [11]. However, the differences in 76 duration of ART and gender did not
 209 affect both parameters (PT and APTT) as observed in this study.

Comment [ZK40]: Do you have any significant results of PT and APTT according to different age groups or gender differences?

Comment [ZK41]: What does this mean?

210 Tuberculosis is a chronic granulomatous infection caused by mycobacterium tuberculosis.
 211 Various inflammatory cells, cytokines and mediators are involved in the formation of
 212 granulomatous lesions encountered in tuberculosis [12] of variety of cytokines. In the study,
 213 the PT of TB patients was shown to be increased significantly (p<0.05) while the APTT was

Comment [ZK42]: Grammar error

214 not significantly increased ($p>0.05$) when compared with the control subjects. Also immune
215 complexes and many other factors elaborated in various infectious diseases (e.g
216 Mycobacterial infection) are shown to induce pro-coagulant tissue factor (TF) expression in
217 monocytes/macrophages and the endothelium which under normal healthy state doesn't
218 express TF [13-15]. This could be the reason for the significant increase in PT, since
219 activation of TF leads to the pathway (extrinsic pathway) that involves prothrombin time
220 (PT) estimation.

221 Lastly, there was also a significant increase in the PT and APTT of HIV and TB- Coinfected
222 subjects ($p<0.05$). when compared with the control subjects. The exact reason for this is not
223 known because much research has not been done specifically involving APTT and PT. A
224 research have shown Bacterial sepsis in association with activation of procoagulant
225 responses, endothelial activation, inhibition of fibrinolysis and decreased anticoagulant
226 response [16]. In the most extreme cases, these change lead to Disseminated intravascular
227 Coagulation (DIC) and micro vascular thrombosis [16, 17]. Much less is known about
228 hemostatic changes during severe HIV-tuberculosis infection.

229

230 CONCLUSION

231 HIV infections have been shown to affect both the Activated partial thromboplastin time and
232 prothrombin time. There is significant alteration in coagulation parameters (particularly PT
233 and APTT) on tuberculosis, lesions as a result of the mycobacterial infection can induce pro-
234 coagulant tissue factor expression which can lead to coagulation defects. HIV-TB co-infection
235 being a complex state can lead to complex alterations in coagulation pathways and even
236 haemostasis generally in the individual involved.

237

238 References

- 239 1. Obeagu EI, Onyenweaku FC, Nwobodo HA, Ochei KC, Ochiabuto OMTB et al.
240 Impact of HIV and Hepatitis Vvirus Coinfection on selected Haematological Markers
241 of the patients in Umuahia, Abia State, Nigeria. *Annals of Clinical and Laboratory*
242 *Research* 5:2.doi:10.21767/2386-5180.1000175.
- 243 2. UNAIDS, WHO . 2007 AIDS epidemic update.2007:10.
- 244 3. Smith JA, Daniel R. Following the path of the virus: the exploitation of
245 host DNA repair mechanisms by retroviruses". *ACS Chem Biol.* 2006; 1
246 (4): 217- 26.
- 247 4. Gilbert PB, McKeague IW, Eisen G, Mullins C, Gueye-NDiaye A,
248 Mboup S, Kanki PJ. Comparison of HIV-1 and HIV-2 infectivity from a
249 prospective cohort study in Senegal".*Statistics in Medicine.* 2003; 22 (4):
250 573-593.
- 251 5. Reeves JD, Dorns RW. Human Immunodeficiency Virus Type 2".*Journal*
252 *of General Virology.* 2002; 83 (Pt 6): 1253-65.
- 253 6. Bergmann S, Flammerschmidt S. Fibrinolysis and host response in
254 bacterial infections.*Thromb Haemost.* 2007; 98: 512-520.
- 255 7. Linder M, Muller-Berghaus G, Lasch LIG.Virus infection and blood

Comment [ZK43]: Grammar check

- 256 coagulation".ThrombDiath hemorrhage. 1970; 120:129-152.
- 257 8. Van Gorp ECM, Suharti C, ten Cate II, Dolmans WMV, Brangjes DPM.
258 Review: Infectious diseases and coagulation disorders. Journal of
259 Infectious diseases. 1999; 180: 176-186.
- 260 9. Omoregie R, Osakue SI, Ihemeje V, Omokaro EU, Ogcferet H.
261 Correlation thromboplastin time among HIV patients in Benin City,
262 Nigeria. West Indian of CD4 count with platelet count, prothrombin time
263 and activated partial med J. 2009;58(5):437
- 264 10.Obeagu EI, Obeagu GU (2015) Effect of CD4 Counts on Coagulation
265 Parameters among HIV Positive Patients in Federal Medical Centre,
266 Owcrri, Nigeria. International Journal of Current Research in Biosciences
267 and Plant Biology 2: 45-49.
- 268 11.Karpatkin S, Nardi M, Green D. Platelet and coagulation defects
269 associated with HIV-1 infection. Thrombosis and Haemostasis.2002; 88:
270 389-401.
- 271 12.Bost TW, Riches DW, Schumacher B. Aveolar macrophages from
272 patients with beryllium diseases and sarcoidosis express increased levels
273 of mRNA for tumor necrosis factor alpha and interleukin-1 beta. Am J
274 Respir cell Molecular Biology. 1994; 10:1506-13.
- 275 13.Pawlinslci R, Mackman N. Cellular sources of tissue factor in
276 endotoxemia and sepsis", Thromb Res 125 Suppl.2010; 1: S70-S73.
- 277 14.Taylor FB, Chang A, Ruf W, Morrissey JFI, Hinshaw LB. LethalE.coli
278 septic shock is prevented by blocking tissue factor with monoclonal
279 antibody". Circ Shock. 1991; 33: 127-134.
- 280 15. Osterud B. Monocytes and hypercoagulable states. Hypercoag Sts. 1995;
281 1-11
- 282 16.Levi M, Van der poll.T.inflammation and coagulation, crit care med.
283 2010;38:S26-34.
- 284 17.Taylor FB jr, Toh CFI, Hoots WK, Wada II, Levi M. Towards definition,
285 clinical and laboratory criteria and a scoring system for Disseminated
286 intravascular coagulation.Thrombotic haemostat. 2001;86-1327-30.

287
288
289